{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:26:45Z","timestamp":1767598005664},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>Eleven genes have been identified that increase the lifetime risk of developing ovarian cancer. The cumulative cancer risk of ovarian cancer varies with the mutation type and age. Ovarian cancer risk management options include surgical risk reduction with salpingo-oophorectomy and a newer step-wise approach with interval salpingectomy and delayed oophorectomy. Women should be counseled on the pros and cons of hysterectomy in the setting of reducing the risk of other cancers; eliminating the risk of endometrial cancer in Lynch Syndrome, potential risk of serous\/serous-like endometrial cancer in <jats:italic toggle=\"yes\">BRCA1<\/jats:italic> carriers, and elimination of progestogen therapy that may increase breast cancer risk.<\/jats:p>","DOI":"10.1097\/grf.0000000000000499","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T07:06:19Z","timestamp":1574665579000},"page":"64-73","source":"Crossref","is-referenced-by-count":6,"title":["Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time"],"prefix":"10.1097","volume":"63","author":[{"given":"CASEY L.","family":"SWANSON","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JAMIE N.","family":"BAKKUM-GAMEZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"R2-20230911","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/humu.22262","article-title":"Cancer risks for MLH1 and MSH2 mutation carriers","volume":"34","author":"Dowty","year":"2013","journal-title":"Hum Mutat"},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","article-title":"Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database","volume":"67","author":"Moller","year":"2018","journal-title":"Gut"},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA"},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2018.78.4777","article-title":"Cancer risks for PMS2-associated Lynch syndrome","volume":"36","author":"Ten Broeke","year":"2018","journal-title":"J Clin Oncol"},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"R10-20230911","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/01.AOG.0000456325.50739.72","article-title":"ACOG Practice Bulletin No. 147: Lynch syndrome","volume":"124","year":"2014","journal-title":"Obstet Gynecol"},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R12-20230911","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"key":"R13-20230911","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/modpathol.2013.212","article-title":"Mullerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-End protocol","volume":"27","author":"Mingels","year":"2014","journal-title":"Mod Pathol"},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/AOG.0000000000003421","article-title":"Health care provider adherence to surgical guidelines for risk-reducing salpingo-oophorectomy","volume":"134","author":"Wilhite","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R17-20230911","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.clbc.2018.09.011","article-title":"Risk reduction and survival benefit of risk-reducing salpingo-oophorectomy in hereditary breast cancer: meta-analysis and systematic review","volume":"19","author":"Xiao","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10549-017-4605-x","article-title":"Predictors of survival for breast cancer patients with a BRCA1 mutation","volume":"168","author":"Narod","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"R19-20230911","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaoncol.2015.0658","article-title":"Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"1","author":"Metcalfe","year":"2015","journal-title":"JAMA Oncol"},{"key":"R20-20230911","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-016-3749-4","article-title":"The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients","volume":"156","author":"Huzarski","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"R21-20230911","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.maturitas.2011.08.001","article-title":"Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review","volume":"70","author":"Finch","year":"2011","journal-title":"Maturitas"},{"key":"R22-20230911","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2010.12.326","article-title":"The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation","volume":"121","author":"Finch","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R23-20230911","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","article-title":"Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer","volume":"23","author":"Madalinska","year":"2005","journal-title":"J Clin Oncol"},{"key":"R24-20230911","doi-asserted-by":"crossref","first-page":"e1361","DOI":"10.1016\/j.clbc.2018.07.015","article-title":"Satisfaction and impact on quality of life of clinical and instrumental surveillance and prophylactic surgery in BRCA-mutation carriers","volume":"18","author":"D\u2019Alonzo","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"R25-20230911","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/gme.0b013e31818888f7","article-title":"Increased cardiovascular mortality after early bilateral oophorectomy","volume":"16","author":"Rivera","year":"2009","journal-title":"Menopause"},{"key":"R26-20230911","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1212\/01.wnl.0000276984.19542.e6","article-title":"Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause","volume":"69","author":"Rocca","year":"2007","journal-title":"Neurology"},{"key":"R27-20230911","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol"},{"key":"R28-20230911","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations: a systematic review of risks and benefits","volume":"153","author":"Gordhandas","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R29-20230911","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","article-title":"The distal fallopian tube: a new model for pelvic serous carcinogenesis","volume":"19","author":"Crum","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R30-20230911","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","article-title":"Long-term health consequences of premature or early menopause and considerations for management","volume":"18","author":"Faubion","year":"2015","journal-title":"Climacteric"},{"key":"R31-20230911","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1940-6207.CAPR-14-0293","article-title":"Salpingectomy as a means to reduce ovarian cancer risk","volume":"8","author":"Daly","year":"2015","journal-title":"Cancer Prev Res (Phila)"},{"key":"R34-20230911","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.clbc.2013.12.010","article-title":"Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer","volume":"14","author":"Pan","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"R36-20230911","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.clbc.2016.06.016","article-title":"Comparing coordinated versus sequential salpingo-oophorectomy for BRCA1 and BRCA2 mutation carriers with breast cancer","volume":"16","author":"Chapman","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"R37-20230911","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/SAP.0b013e3181a2c6bd","article-title":"Safety and efficacy of perforator flap breast reconstruction with combined intraabdominal procedures","volume":"64","author":"Casey","year":"2010","journal-title":"Ann Plast Surg"},{"key":"R38-20230911","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/SAP.0000000000000156","article-title":"Outcomes and cost analysis in high-risk patients undergoing simultaneous free flap breast reconstruction and gynecologic procedures","volume":"75","author":"Del Corral","year":"2015","journal-title":"Ann Plast Surg"},{"key":"R39-20230911","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10549-018-4818-7","article-title":"Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database","volume":"171","author":"Elmi","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"R40-20230911","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1245\/s10434-016-5479-6","article-title":"Outcomes of concurrent breast and gynecologic risk reduction surgery","volume":"24","author":"Ma","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"R41-20230911","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2013.03.027","article-title":"The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study","volume":"130","author":"Segev","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R42-20230911","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"R44-20230911","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"R45-20230911","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamaoncol.2015.0494","article-title":"Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women\u2019s Health Initiative Randomized Clinical Trials","volume":"1","author":"Chlebowski","year":"2015","journal-title":"JAMA Oncol"},{"key":"R46-20230911","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ygyno.2017.03.025","article-title":"Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous\/serous-like uterine cancers in BRCA1 mutation carriers","volume":"145","author":"Havrilesky","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R47-20230911","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.gore.2018.10.003","article-title":"Hysterectomy at the time of risk-reducing surgery in BRCA carriers","volume":"26","author":"Nair","year":"2018","journal-title":"Gynecol Oncol Rep"},{"key":"R48-20230911","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s10897-018-0264-2","article-title":"Uptake of preimplantation genetic diagnosis in female BRCA1 and BRCA2 mutation carriers","volume":"27","author":"Mor","year":"2018","journal-title":"J Genet Couns"},{"key":"R49-20230911","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4103\/jhrs.JHRS_132_18","article-title":"Preimplantation genetic testing: its evolution, where are we today?","volume":"11","author":"Parikh","year":"2018","journal-title":"J Hum Reprod Sci"},{"key":"R50-20230911","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2009.24.2057","article-title":"Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast\/ovarian cancer risks","volume":"28","author":"Oktay","year":"2010","journal-title":"J Clin Oncol"},{"key":"R51-20230911","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/jayao.2016.0009","article-title":"Association of BRCA1 mutations with impaired ovarian reserve: connection between infertility and breast\/ovarian cancer risk","volume":"5","author":"Giordano","year":"2016","journal-title":"J Adolesc Young Adult Oncol"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:25:16Z","timestamp":1694420716000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000499","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,22]]}}}